Open Site Navigation

EMERCELL is a biotech company bridging immunotherapy research projects to first pharmaceutical development steps

NK-001 Product & Technology

EMERCELL is developing off-the-shelf cell immunotherapy NK-based to be used in synergy with Monoclonal Antibodies (MAbs) to treat cancer. This new and innovative cell therapy called NK-001 consists of allogeneic Natural Killer (NK) cells derived from compatible pooled Umbilical Cord Blood (UCBs)  activated & amplified ex vivo according to a patented process.

Contact

Information

Email : contact@emercell.com 
Tél : +(33) 6.14.77.39.21

Head office

36 Chemin de l’hôpital
34270 St Mathieu de Tréviers

Laboratory

IRMB – CHRU de Montpellier
80 avenue Augustin Fliche
34295 Montpellier

Tel : +(33) 4.67.33.04.82

Thank you for your message

Capture d’écran 2022-04-25 à 18.25.21.png

Mission

EMERCELL ’s focus is to complete the pharmaceutical development of innovative cell therapy products, up to the clinical proof of concept

 

Immunotherapy and cell therapy are highly potent therapeutic ways to help body’s immune system and to better fit the current therapeutic needs

 

The first project of EMERCELL is NK-001, in oncology area

Capture d’écran 2022-04-25 à 18.25.21.png

News & Events

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

Jun 20, 2022

EMERCELL Signs Strategic Partnership with Onward Therapeutics for the Development of its NK Cell Therapy Technology

Feb 17, 2021

NK-001 Product & Technology

EMERCELL is developing off-the-shelf cell immunotherapy NK-based to be used in synergy with Monoclonal Antibodies (MAbs) to treat cancer. This new and innovative cell therapy called NK-001 consists of allogeneic Natural Killer (NK) cells derived from compatible pooled Umbilical Cord Blood (UCBs)  activated & amplified ex vivo according to a patented process.

Pooled UCBs
Patented production process
Off the shelf frozen NK-001 cells
MAb + thawed NK-001 infusion